1. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
   E. Ciruelos et al, 2020, Clin Transl Oncol CrossRef
2. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
   Fatih YILDIZ et al, 2020 CrossRef
3. Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
   Armando Orlandi et al, 2020, JPM CrossRef
4. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review.
   Sergiusz Łukasiewicz et al, 2021, Cancers (Basel) CrossRef
5. New and Emerging Targeted Therapies for Advanced Breast Cancer
   Kristie H. Lau et al, 2022, IJMS CrossRef
6. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association.
   Tochi M Okwuosa et al, 2021, Circ Genom Precis Med CrossRef